Marc A Pfeffer, ACC 2021 – Findings from PARADISE-MI
We were delighted to have the opportunity to speak with Prof. Marc A Pfeffer (Distinguished Dzau Professor of Medicine, Harvard Medical School, Boston, MA, US) to discuss the PARADISE-MI trial investigating sacubitril/valsartan vs. ramipril in a contemporary enriched AMI population, presented at ACC 2021.
Abstract Title: Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction – PARADISE-MI
Speaker disclosures: Marc A Pfeffer has received consulting fees/honorarium from: Novo Nordisk, AstraZeneca Pharmaceuticals, DalCor, GlaxoSmithKline, Sanofi-Aventis, Boehringer Ingelheim-Lilly, Corvidia, Peerbridge, Novartis; Research/research grants from: Novartis; Other financial benefit: Novartis, DalCor
Support: Interview and filming supported by Touch Medical Media and conducted by Nicola Cartridge
Filmed during a remote video call with Professor Marc A Pfeffer as a highlight of ACC 2021, May 2021.
Share this Video
Related Videos In Cardiovascular Disease
John Forrest, ACC 2023: Evolut low risk trial, transcatheter versus surgical aortic valve replacement in patients at low surgical risk
The Evolut low risk trial aimed to compare transcatheter versus surgical aortic valve replacement in patients who were at low risk for surgery. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to discuss the eligibility criteria, the key findings and the outlook for […]
John Forrest, ACC 2023: The treatment paradigm for patients with aortic stenosis
The treatment paradigm for aortic stenosis has developed dramatically in the past decade. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to outline and discuss the developments. Dr Forrest presented an abstract entitled ‘Transcatheter Versus Surgical Aortic Valve Replacement In Aortic Stenosis Patients […]
Steven Nissen, ACC 2023: Lipid-lowering therapies – current and future options
Many lipid-lowering therapies exist, such as statins to manage and reduce lipid levels. While statins are the most commonly used medication, some patients may need additional interventions to lower their LDL cholesterol levels. In this touchCARDIO interview, we speak with Prof. Steven Nissen (Cleveland Clinic, Cleveland, OH, USA) to explore current and developing novel lipid-lowering […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!